CommercialPrior AuthLow impact
Marplan (isocarboxazid)
Blue Cross & Blue Shield of Mississippi·MS · Psychiatry, Family Medicine, Internal Medicine·Medical Policy
Effective date
Jun 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their prior authorization policy for Marplan (isocarboxazid), an MAOI antidepressant. The policy now requires prior auth with specific criteria including age ≥16, documented major depressive disorder, failure of at least two antidepressants, and no contraindicated drug combinations.
Action Required
By June 1, 2025: Billing team must update prior authorization requirements for Marplan (isocarboxazid) prescriptions for BCBS Mississippi patients. Ensure providers document: patient age ≥16, major depressive disorder diagnosis, failure of at least two prior antidepressants, no contraindicated drug combinations, and dosage within FDA limits. Update encounter forms to include these documentation requirements. Claims without proper prior auth will be denied.